Literature DB >> 11214134

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.

A Lafeuillade, G Hittinger, S Chadapaud.   

Abstract

In two of 15 patients coinfected with HIV and hepatitis C virus who received interferon-alpha plus ribavirin in addition to HAART, we observed multiorgan dysfunction and lactic acidaemia. As ribavirin is a nucleoside analogue, an increased risk of mitochondrial toxicity can be induced in HIV-infected patients already treated with nucleoside analogues, leading to clinical deterioration in some cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11214134     DOI: 10.1016/S0140-6736(00)03618-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

1.  Ribavirin in the treatment of SARS: A new trick for an old drug?

Authors:  Gideon Koren; Susan King; Sandra Knowles; Elizabeth Phillips
Journal:  CMAJ       Date:  2003-05-13       Impact factor: 8.262

Review 2.  When to treat patients with chronic hepatitis C.

Authors:  Jenny Heathcote; Alnoor Ramji
Journal:  Curr Gastroenterol Rep       Date:  2004-08

3.  Update on Hepatitis B and C Coinfection in HIV.

Authors:  Patrick Yachimski; Raymond T Chung
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 4.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

Review 5.  2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-08-10

Review 6.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

7.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.

Authors:  Laure Valerio; Yazdan Yazdanpanah; Isabelle Poizot-Martin; Eric Rosenthal; Catherine Marimoutou; Jean-Albert Gastaut; Albert Tran; Pierre Dellamonica; Kenneth A Freedberg; Christian Pradier
Journal:  J Acquir Immune Defic Syndr       Date:  2008-01-01       Impact factor: 3.731

9.  The management of chronic viral hepatitis: A Canadian consensus conference 2004.

Authors:  Morris Sherman; Vincent Bain; Jean-Pierre Villeneuve; Robert P Myers; Curtis Cooper; Steven Martin; Catherine Lowe
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-11       Impact factor: 2.471

Review 10.  Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations.

Authors:  Miriam Romero; Mayte Pérez-Olmeda; Javier García-Samaniego; Vicente Soriano
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.